Company intelligence / Profile preview

Équilibre Biopharmaceuticals

New York, New York, United Statesequilibre.ca ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

EQU-001 is currently in Phase II clinical trials for epilepsy. According to GlobalData, Phase II drugs for Epilepsy have a 69% phase transition success rate for progressing into Phase III.

Therapeutic areas: Neurology
Modalities: Small molecule drugs
Industry: Biotech

Beyond the preview

Go deeper on Équilibre Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Équilibre Biopharmaceuticals.

Explore the full profile